| 产品描述: | Hcyb1 is a highly selective, orally active PDE2 inhibitor. Hcyb1 has a highly selective inhibition of PDE2A (IC50=0.57 μM) and over 250-fold selectivity against other recombinant PDE family members. Hcyb1 produces neuroprotective and antidepressant‐like effects most likely mediated by cAMP/cGMP-CREB-BDNF signaling. |
| 靶点: |
PDE2 |
| 体外研究: |
Hcyb1 (0.5, 1, and 2 mg/kg, i.g.) decreases the immobility time in both forced swimming and tail suspension tests, without altering locomotor activity. |
| 体内研究: |
Hcyb1 (1~100 nM; 10 minutes) increases cGMP levels by 1.7~2.3 folds. Hcyb1 (1 nM; 24 hours) increases both cGMP and cAMP levels. Hcyb1 (24 hours) treatment also increases the levels of phosphorylation of CREB and BDNF in HT-22 cells. Hcyb1 promotes HT-22 cell viability and increase the cGMP and cAMP accumulation in HT-22 cells. Hcyb1 exhibits the concentration- and time-dependent effects on cell viability in HT-22 cells. |
| 保存条件: |
-80°C 6个月;-20°C 1个月 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.629 ml |
13.143 ml |
26.285 ml |
| 5 mM |
0.526 ml |
2.629 ml |
5.257 ml |
| 10 mM |
0.263 ml |
1.314 ml |
2.629 ml |
| 50 mM |
0.053 ml |
0.263 ml |
0.526 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |